Journal article
Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis
Abstract
In a randomized, open-label, controlled, multicentre study, the clinical and bacteriological efficacy, safety and tolerability of oral gemifloxacin (320 mg once daily, 5 days) was compared with sequential intravenous (i.v.) ceftriaxone (1 g once daily, maximum 3 days) followed by oral cefuroxime axetil (500 mg twice daily, maximum 7 days) in adult hospitalized patients with acute exacerbations of chronic bronchitis (AECB) (n = 274). The …
Authors
WILSON R; LANGAN C; BALL P; BATEMAN K; PYPSTRA R; GROUP TGCS
Journal
Respiratory Medicine, Vol. 97, No. 3, pp. 242–249
Publisher
Elsevier
Publication Date
3 2003
DOI
10.1053/rmed.2003.1435
ISSN
0954-6111
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Administration, OralAdultAgedAged, 80 and overAnti-Bacterial AgentsAnti-Infective AgentsBacterial InfectionsBronchitis, ChronicCeftriaxoneCefuroximeDrug Therapy, CombinationFemaleFluoroquinolonesForced Expiratory VolumeGemifloxacinHospitalizationHumansInfusions, IntravenousLength of StayMaleMiddle AgedNaphthyridinesTreatment Outcome